Compare LAZ & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LAZ | IRTC |
|---|---|---|
| Founded | 1848 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.8B |
| IPO Year | 2005 | 2016 |
| Metric | LAZ | IRTC |
|---|---|---|
| Price | $54.76 | $152.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $55.38 | ★ $217.31 |
| AVG Volume (30 Days) | ★ 1.0M | 797.7K |
| Earning Date | 01-29-2026 | 02-19-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $3,098,847,000.00 | $702,573,000.00 |
| Revenue This Year | $15.79 | $27.50 |
| Revenue Next Year | $12.49 | $17.10 |
| P/E Ratio | $26.25 | ★ N/A |
| Revenue Growth | 1.64 | ★ 25.45 |
| 52 Week Low | $31.97 | $92.52 |
| 52 Week High | $58.75 | $212.00 |
| Indicator | LAZ | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 57.25 | 41.66 |
| Support Level | $50.93 | $144.79 |
| Resistance Level | $58.75 | $153.81 |
| Average True Range (ATR) | 2.20 | 6.98 |
| MACD | 0.25 | -0.13 |
| Stochastic Oscillator | 56.39 | 34.84 |
Lazard Inc has a storied history that can be traced back to 1848. The company's revenue is fairly evenly split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily driven by equities (over 80% of assets under management), has an international focus, and targets institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.
iRhythm Holdings Inc formerly, iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.